SureTrader Advertisement PRTC
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 32
Posts 5,197
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Stocks End Lower, Post Modest Monthly Gains
Consumer spending leaps in April; house prices jump in March U.S. stocks ended mostly lower on Tuesday, as investors turned cautious on the...
Top Equities Stories Of The Day
SciQuest to Be Taken Private by Accel-KKR
United Flies Further Into China
Cliffs Natural in Deal to Supply ArcelorMittal
China's Xiaomi to Buy 1,500 Patents From Microsoft
Icahn Takes Stake in Allergan
Personnel Move Shows Bank of America Beefing Up Chemical Focus in Germany
U.S. Car-Buying Boom: Time to Downshift? -- Ahead of the Tape
Tata Motors Investment in New Models Shows Results
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 201700 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist